ethyl 3-bromo-4-oxo-4-(pyridin-2-yl)butanoate | 1427728-65-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: ethyl 3-bromo-4-oxo-4-(pyridin-2-yl)butanoate
• 英文别名: Ethyl 3-bromo-4-oxo-4-pyridin-2-ylbutanoate；ethyl 3-bromo-4-oxo-4-pyridin-2-ylbutanoate
• CAS: 1427728-65-1
• 化学式: C₁₁H₁₂BrNO₃
• 分子量: 286.125
• InChiKey: HZZVUEHZTDTOAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  56.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 3-bromo-4-oxo-4-(pyridin-2-yl)butanoate 在 甲醇 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 2-[2-[(E)-(4-oxo-1,3-thiazolidin-2-ylidene)methyl]-4-pyridin-2-yl-1,3-thiazol-5-yl]acetic acid
  参考文献：
  名称：

  A series of thiazole derivatives bearing thiazolidin-4-one as non-competitive ADAMTS-5 (aggrecanase-2) inhibitors

  摘要：

  A series of thiazole bearing thiazolidin-4-one was discovered via high-throughput screening as non-competitive inhibitors of ADAMTS-5. Compound 31 appeared to give the best ADAMTS-5 inhibition and good selectivity over other metalloproteases. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.01.121
• 作为产物：
  描述：

  4-羰基-4-(2-吡啶基)丁酸 在 硫酸 、 溴 、 溶剂黄146 作用下， 生成 ethyl 3-bromo-4-oxo-4-(pyridin-2-yl)butanoate
  参考文献：
  名称：

  A series of thiazole derivatives bearing thiazolidin-4-one as non-competitive ADAMTS-5 (aggrecanase-2) inhibitors

  摘要：

  A series of thiazole bearing thiazolidin-4-one was discovered via high-throughput screening as non-competitive inhibitors of ADAMTS-5. Compound 31 appeared to give the best ADAMTS-5 inhibition and good selectivity over other metalloproteases. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.01.121

文献信息

• [EN] SUBSTITUTED AMINOTHIAZOLES<br/>[FR] AMINOTHIAZOLES SUBSTITUÉS
  申请人：BARUCH S BLUMBERG INST

  公开号：WO2018013508A1

  公开（公告）日：2018-01-18

  Described herein are substituted aminothiazoles, compositions comprising same; and methods of making and using same.

  本文描述了替代氨基噻唑，包括相同成分的组合物；以及制备和使用相同的方法。
• Substituted aminothiazoles
  申请人：BARUCH S. BLUMBERG INSTITUTE

  公开号：US10913734B2

  公开（公告）日：2021-02-09

  Described herein are substituted aminothiazoles, compositions comprising same; and methods of making and using same.

  本文描述了取代的氨基噻唑、包含取代的氨基噻唑的组合物以及制造和使用取代的氨基噻唑的方法。
• Novel substituted aminothiazoles as potent and selective anti-hepatocellular carcinoma agents
  作者：Huagang Lu、John Rogowskyj、Wenquan Yu、Anu Venkatesh、Noshena Khan、Shigeki Nakagawa、Nicolas Goossens、Anna P. Koh、Takaaki Higashi、Ganesh Gunasekaran、Myron E. Schwarz、Spiros P. Hiotis、Xiaodong Xu、William Kinney、Yujin Hoshida、Timothy Block、Andrea Cuconati、Yanming Du

  DOI：10.1016/j.bmcl.2016.10.015

  日期：2016.12

  Based on our previous identification of a disubstituted aminothiazole termed HBF-0079 with promising selective toxicity for HCC-derived cell lines versus non-HCC liver lines, a series of tri-substituted aminothiazole derivatives were prepared and evaluated. This work resulted in the discovery of isopropyl 4-(pyrazin-2-yl)-2-(pyrimidin-2-ylamino) thiazole-5-carboxylate, 14, which displayed EC50 value of 0.11 mu M and more than 450 times of selectivity, and its methyl carbonate prodrug 24 with improved solubility in organic solvents. Furthermore, 14, was shown to reduce the proliferation of several liver cancer cells derived directly from patients. (C) 2016 Elsevier Ltd. All rights reserved.
• SUBSTITUTED AMINOTHIAZOLES
  申请人：Baruch S. Blumberg Institute

  公开号：EP3481810A1

  公开（公告）日：2019-05-15
• A series of thiazole derivatives bearing thiazolidin-4-one as non-competitive ADAMTS-5 (aggrecanase-2) inhibitors
  作者：Masakazu Atobe、Naomi Maekawara、Noriko Ishiguro、Shinya Sogame、Yoshihito Suenaga、Masashi Kawanishi、Hiroko Suzuki、Norimasa Jinno、Eiichi Tanaka、Shiro Miyoshi

  DOI：10.1016/j.bmcl.2013.01.121

  日期：2013.4

  A series of thiazole bearing thiazolidin-4-one was discovered via high-throughput screening as non-competitive inhibitors of ADAMTS-5. Compound 31 appeared to give the best ADAMTS-5 inhibition and good selectivity over other metalloproteases. (C) 2013 Elsevier Ltd. All rights reserved.